Theragnostics in Neuroendocrine Tumors

Margarida Rodrigues; Hanna Svirydenka; Irene Virgolini

doi:10.1016/j.cpet.2021.03.001

Theragnostics in Neuroendocrine Tumors

PET Clin. 2021 Jul;16(3):365-373. doi: 10.1016/j.cpet.2021.03.001.

Authors

Margarida Rodrigues¹, Hanna Svirydenka², Irene Virgolini²

Affiliations

¹ Department of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, Innsbruck 6020, Austria. Electronic address: Margarida.Rodrigues-Radischat@i-med.ac.at.
² Department of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, Innsbruck 6020, Austria.

PMID: 34053580
DOI: 10.1016/j.cpet.2021.03.001

Abstract

Several studies have demonstrated the effectiveness of somatostatin receptor (SSTR)-targeted imaging for diagnosis, staging, evaluating the possibility of treatment with cold somatostatin analogs, as well peptide receptor radionuclide therapy (PRRT), and evaluation of treatment response. PET with ⁶⁸Ga-labeled somatostatin analogs provides excellent sensitivity and specificity for diagnosing and staging neuroendocrine tumors (NETs). Metabolic imaging with PET with fludeoxyglucose ¹⁸F/computed tomography (CT) complements the molecular imaging with ⁶⁸Ga-SSTR PET/CT toward a personalized therapy in NET patients. The documented response rate of PRRT in NET summing up complete response, partial response, minor response, and stable disease is 70% to 80%.

Keywords: (177)Lu-PRRT; (18)F-FDG; (68)Ga-DOTA-TOC; (90)Y-DOTATATE; Neuroendocrine tumor; Peptide receptor radionuclide therapy; Theragnostics.

Publication types

Review

MeSH terms

Humans
Neuroendocrine Tumors* / diagnostic imaging
Organometallic Compounds*
Positron Emission Tomography Computed Tomography
Receptors, Somatostatin
Tomography, X-Ray Computed

Substances

Organometallic Compounds
Receptors, Somatostatin